Kathleen Brown, MD
Clinical Cardiac Electrophysiology · Pueblo, CONPI 1881821312
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (27.6%), speaking fees and consulting fees — rather than concentrated in one kind of arrangement. Boston Scientific accounts for 80.6% of it on its own, with 23 other manufacturers making up the rest.
Across 467 payments — averaging $143.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$54K
- Medtronic$7K
- Abbott$4K
- Novartis$174
- Pfizer$159
- Acutus Medical, Inc.$159
- plus $1K from 18 others
What the payments were for
- Consulting fees$15,62523%
- Speaking & faculty fees$17,37526%
- Travel & lodging$15,43823%
- Food & beverage$18,43828%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 221 | $53,900 |
| Medtronic(2 entities) | 97 | $6,702 |
| Abbott | 73 | $4,434 |
| Novartis | 9 | $174 |
| Pfizer | 8 | $159 |
| Acutus Medical, Inc. | 2 | $159 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 9 | $143 |
| Impulse Dynamics (USA) Inc. | 2 | $139 |
| Biosense Webster, Inc. | 2 | $136 |
| Amgen | 9 | $132 |
| Cardiva Medical, Inc. | 4 | $127 |
| Edwards Lifesciences | 2 | $125 |
| Philips North America LLC | 6 | $117 |
| E.r. Squibb & Sons, L.L.C. | 7 | $116 |
| Alnylam Pharmaceuticals Inc. | 3 | $74 |
| Johnson & Johnson | 4 | $62 |
| Atricure, Inc. | 1 | $48 |
| AstraZeneca | 2 | $24 |
| Lilly USA, LLC | 1 | $21 |
| Sanofi | 1 | $20 |
| Gilead | 1 | $19 |
| Cardiofocus, Inc. | 1 | $17 |
| Boehringer Ingelheim | 1 | $15 |
| Sanofi-aventis U.S. LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- WATCHMAN Access System$21,447
- WATCHMAN FLX$18,547
- GENERAL - THERAPIES$3,660
- Farapulse$3,258
- LINQ II$1,789
- ENSITE PRECISION$1,400
- Watchman$1,167
- Rhythmia Mapping System$1,102
- Micra$990
- Ensite Cardiac Mapping System$410
- ENSITE$398
- RESONATE$340
- Reveal LINQ$244
- AMPLATZER Occluders$232
- Confirm Rx$155
- EnSite Precision Cardiac Mapping System$151
- GENERAL TACHY$145
- ADVISOR$142
- AMPLATZER$135
- JOT DX$124
How this compares
$66,877 in reported general payments places this provider in the 80th percentile of 66 clinical cardiac electrophysiology providers in Colorado.
See all clinical cardiac electrophysiology providers in Colorado →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 454 | $549,400 |
| VyndamaxTafamidis | 16 | $541,303 |
| XareltoRivaroxaban | 46 | $60,353 |
| EntrestoSacubitril/Valsartan | 23 | $31,299 |
| JardianceEmpagliflozin | 20 | $27,998 |
| Repatha SureclickEvolocumab | 24 | $15,757 |
| Flecainide Acetate | 124 | $7,157 |
| FarxigaDapagliflozin Propanediol | 12 | $6,866 |
| PradaxaDabigatran Etexilate Mesylate | 25 | $5,060 |
| Metoprolol Succinate | 206 | $4,095 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 38 | $1,516 |
| Carvedilol | 143 | $1,339 |
| ClopidogrelClopidogrel Bisulfate | 109 | $1,315 |
| Verapamil ErVerapamil Hcl | 33 | $1,167 |
| Droxidopa | 11 | $1,075 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Vyndamax | $159 | $1,090,702470 claims |
| Johnson & JohnsonXarelto | $62 | $60,35346 claims |
| Boehringer IngelheimJardiance, Pradaxa | $15 | $33,05845 claims |
| NovartisEntresto | $174 | $31,29923 claims |
| AstraZenecaFarxiga | $24 | $6,86612 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 66 clinical cardiac electrophysiology providers in Colorado.
Other clinical cardiac electrophysiology in Pueblo
- Charles StoutPueblo$9K
- Srikanth SundaramLittleton$493K
- Bradley MikaelianColorado Springs$364K
- Wendy TzouAurora$350K
- Christopher PorterfieldAurora$340K
- Lohit GargAurora$147K
- Ethan EllisFort Collins$144K
- Ganesh VenkataramanLakewood$127K
- Margot VlokaAurora$104K
- Benjamin SteinbergDenver$98K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.